Description：Enzyme Immunoassay for the quantitative determination of AntiInfliximab in serum, plasma and cell culture supernatant.
Infliximab is a monoclonal antibody which has high specificity for TNFα, and does not neutralize TNF beta.
Infliximab causes programmed cell death of TNFα-expressing activated T lymphocytes, an important cell type mediating inflammation; hence it is generally assumed that resolution of activated T cells by Infliximab explains its efficacy in Crohn's disease.
Anti-Drug Antibodies （ADA） may induce unwanted side effects in biopharmaceuticals.
Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies.
ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy.
These effects result from the generation of
drug-induced （neutralizing） autoantibodies against infliximab and can be responsible for allergic reaction, or even anaphylactic shock.
This ELISA kit detects antibodies for Anti-Infliximab and may be used for monitoring immunogenicity.
Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well.
About the kit：
- Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％
- Ready to use with a standard protocol with break-apart pre-coated wells
- Validated as per US FDA guidelines for Bioassays
- Optimized for matrix effects to ensure higher sensitivity.
- Shelf life： 1 year
The method employs the quantitative sandwich enzyme immunoassay technique.
Infliximab is pre-coated onto microwells.
Samples and standards are pipetted into microwells and antibodies to Infliximab present in the sample are bound by the capture antibody.
Then, a HRP （horseradish peroxidase） conjugated Infliximab is pipetted and incubated.
After washing microwells in order to remove any non-specific binding, the ready to use substrate solution （TMB） is added to microwells and color develops proportionally to the
amount of Anti-Infliximab in the sample.
Color development is then stopped by addition of stop solution.
